Stay updated with breaking news from ரூபர்ட் வெஸ்ஸி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Search jobs 06-May-2021 Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science ecosystem in collaboration with Bristol Myers Squibb DGAP-News: Evotec SE / Key word(s): Miscellaneous 06.05.2021 / 07:30 beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK THE COLLABORATION LEVERAGES EVOTEC S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR Hamburg, Germany, 06 May 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportuniti ....
Date Time Partnership launched to fast track drug discovery The University of Nottingham is part of a new industry collaboration launched to accelerate drug discovery projects that will fast track research from lab to patient. The University of Nottingham is one of four universities selected by drug development company Evotec SE and global pharmaceutical company Bristol Myers Squibb to be part of the newly formed beLAB1407. Evotec, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Nottingham, Birmingham, Edinburgh and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the crea ....
Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Evotec launches 'beLAB2122', translating academic innovation from leading German life science region pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 13, 2021 beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122 HAMBURG, GERMANY / / April 13, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. ....